Riskpilot← Back to searchSign inGet full accessJohan Flygare Biomedical Consulting AB
ABActiveOrg 5592652837Murarevägen 15Engineering activities and related technical consultancy · NACE 7112Est. 20200 employees
Revenue 2024
SEK 84K
-56% vs 2023
EBITDA margin
52.4%
-72% vs 2023
Equity ratio
88.1%
Financial strength
Net profit 2024
SEK 34K
-72% vs 2023
| Revenue | SEK 84K | -56% |
| EBITDA | SEK 44K | -72% |
| Net profit | SEK 34K | -72% |
| Total assets | SEK 118K | -32% |
| Equity | SEK 104K | -31% |
| Employees | 0 | — |
Legal name
Johan Flygare Biomedical Consulting AB
Org number
5592652837
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
30 juli 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva konsultverksamhet inom biomedicin, läkemedelsutveckling och därmed förenlig verksamhet.
Address
Murarevägen 15
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 220 | 240 | 192 | 84 |
| Staff expenses | — | — | — | — |
| EBITDA | 202 | 168 | 156 | 44 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | 202 | 168 | 156 | 44 |
| Net financials | −10 | −2 | −1 | −1 |
| Profit before tax | 192 | 167 | 155 | 43 |
| Tax | −41 | −0 | −32 | −9 |
| Net profit | 151 | 167 | 123 | 34 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 195 | 188 | 174 | 118 |
| Equity | 176 | 159 | 150 | 104 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 19 | 30 | 24 | 14 |
| Total debt | 19 | 30 | 24 | 14 |
EBITDA margin
52.4%
This company
15.8%
Market median
+232% vs market
20212024
Equity ratio
88.1%
This company
38.2%
Market median
+131% vs market
20212024
Return on equity
32.7%
This company
18.4%
Market median
+78% vs market
20212024
Net profit margin
40.5%
This company
8.1%
Market median
+400% vs market
20212024
Asset turnover
0.71×
This company
1.12×
Market median
-37% vs market
20212024
Debt / equity
0.13×
This company
0.62×
Market median
+79% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (4) | ||
| Deputy Board Member | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Johan Flygare Biomedical Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Johan Flygare | Board of Directors | 0 companies |
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Anna Kristina Dyrvold Flygare | Deputy Board Member | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Nina Marika Wodzinski | Board of Directors | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |